Chaim Hurvitz
CIK: 0001630542
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NRXP
NRX Pharmaceuticals, Inc.
Director
Discretionary Trading P&L
Holdings
About Hurvitz Chaim
Hurvitz Chaim (SEC CIK 0001630542) files insider reports with the SEC as Director of NRX Pharmaceuticals, Inc. (NRXP).
Signal8 holds 1 ownership filing by Hurvitz Chaim, a Form 4, filed on Sep 10, 2025. Those filings report 1 transaction, the latest on Apr 9, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Hurvitz Chaim's filings is in WILMINGTON, DE.
Recent filings by Hurvitz Chaim
- Apr 9, 2025: Grant or award of NRXP derivative securities (Form 4, code A).
Other insiders filing for NRX Pharmaceuticals, Inc. (NRXP)
- Casper Joseph Michael, Chief Operating Officer
- Javitt Jonathan C, Chairman and Chief Scientist
- McBride Dennis, Director
- Flynn Patrick John, Director
- B Group, Inc., 10% Owner
- ABRAMS MICHAEL S, Chief Financial Officer